Date of Publication

1-21-2015

Abstract

Background:

Hepatitis C (HCV)

Viral infection of the liver spread primarily via blood-to-blood contact (e.g., intravenous drug use (IVDU))

United States: 3.2 million chronic HCV infections (2010)

Vermont: 1.63 cases per 1000 people (2012-2013)

Barriers to Care

Exclusion of current IV drug users from HCV treatment programs despite their high rates of infection

Lack of support, causing decreased treatment adherence

Poor access to treatment: cost, transportation, competing priorities of housing, addiction management, and food

HIV and HCV

Research has shown that the multidisciplinary and integrated HIV model is appropriate for HCV

Vermont CARES

Non-profit organization that provides comprehensive services to clients with HIV in Vermont

Advisor(s)

Jerry Larrabee, MD, University of Vermont College of Medicine

Peter Jacobsen, Vermont CARES

Agency

Vermont CARES

Subjects

Access to Health Services, HIV, Immunization and Infectious Diseases, Public Health Infrastructure

Notes

Presented at the 2016 APHA Annual Meeting & Expo, Denver, CO, November 2, 2015.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License